Literature DB >> 18642971

A new preclinical 3-dimensional agarose colony formation assay.

Yoshinori Kajiwara1, Sonali Panchabhai, Victor A Levin.   

Abstract

The evaluation of new drug treatments and combination treatments for gliomas and other cancers requires a robust means to interrogate wide dose ranges and varying times of drug exposure without stain-inactivation of the cells (colonies). To this end, we developed a 3-dimensional (3D) colony formation assay that makes use of GelCount technology, a new cell colony counter for gels and soft agars. We used U251MG, SNB19, and LNZ308 glioma cell lines and MiaPaCa pancreas adenocarcinoma and SW480 colon adenocarcinoma cell lines. Colonies were grown in a two-tiered agarose that had 0.7% agarose on the bottom and 0.3% agarose on top. We then studied the effects of DFMO, carboplatin, and SAHA over a 3-log dose range and over multiple days of drug exposure. Using GelCount we approximated the area under the curve (AUC) of colony volumes as the sum of colony volumes (microm2xOD) in each plate to calculate IC50 values. Adenocarcinoma colonies were recognized by GelCount scanning at 3-4 days, while it took 6-7 days to detect glioma colonies. The growth rate of MiaPaCa and SW480 cells was rapid, with 100 colonies counted in 5-6 days; glioma cells grew more slowly, with 100 colonies counted in 9-10 days. Reliable log dose versus AUC curves were observed for all drugs studied. In conclusion, the GelCount method that we describe is more quantitative than traditional colony assays and allows precise study of drug effects with respect to both dose and time of exposure using fewer culture plates.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18642971     DOI: 10.1177/153303460800700407

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  9 in total

1.  Access to the nucleus and functional association with c-Myc is required for the full oncogenic potential of ΔEGFR/EGFRvIII.

Authors:  Anupama E Gururaj; Laura Gibson; Sonali Panchabhai; MingHui Bai; Ganiraju Manyam; Yue Lu; Khatri Latha; Marta L Rojas; Yeohyeon Hwang; Shoudan Liang; Oliver Bogler
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

2.  Proteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer.

Authors:  Daniel J McGrail; Jeannine Garnett; Jun Yin; Hui Dai; David J H Shih; Truong Nguyen Anh Lam; Yang Li; Chaoyang Sun; Yongsheng Li; Rosemarie Schmandt; Ji Yuan Wu; Limei Hu; Yulong Liang; Guang Peng; Eric Jonasch; David Menter; Melinda S Yates; Scott Kopetz; Karen H Lu; Russell Broaddus; Gordon B Mills; Nidhi Sahni; Shiaw-Yih Lin
Journal:  Cancer Cell       Date:  2020-02-27       Impact factor: 31.743

3.  Transfection of PDCD5 effect on the biological behavior of tumor cells and sensitized gastric cancer cells to cisplatin-induced apoptosis.

Authors:  Hui-Yu Xu; Zhi-Wei Chen; Yuan-Ming Pan; Li Fan; Jie Guan; You-Yong Lu
Journal:  Dig Dis Sci       Date:  2012-02-23       Impact factor: 3.199

4.  Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.

Authors:  Jeannine Garnett; Vaibhav Chumbalkar; Brian Vaillant; Anupama E Gururaj; Kristen S Hill; Khatri Latha; Jun Yao; Waldemar Priebe; Howard Colman; Lisa A Elferink; Oliver Bogler
Journal:  Neoplasia       Date:  2013-01       Impact factor: 5.715

5.  Different changes in protein and phosphoprotein levels result from serum starvation of high-grade glioma and adenocarcinoma cell lines.

Authors:  Victor A Levin; Sonali C Panchabhai; Li Shen; Steven M Kornblau; Yihua Qiu; Keith A Baggerly
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

6.  Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells.

Authors:  Yoshinori Kajiwara; Sonali Panchabhai; Diane D Liu; Maiying Kong; J Jack Lee; Victor A Levin
Journal:  Technol Cancer Res Treat       Date:  2009-04

7.  Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells.

Authors:  Takashi Shingu; Lindsay Holmes; Verlene Henry; Qianghu Wang; Khatri Latha; Anupama E Gururaj; Laura A Gibson; Tiffany Doucette; Frederick F Lang; Ganesh Rao; Liang Yuan; Erik P Sulman; Nicholas P Farrell; Waldemar Priebe; Kenneth R Hess; Yaoqi A Wang; Jian Hu; Oliver Bögler
Journal:  J Transl Med       Date:  2016-02-09       Impact factor: 5.531

8.  Knockdown of lysine (K)-specific demethylase 2B KDM2B inhibits glycolysis and induces autophagy in lung squamous cell carcinoma cells by regulating the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway.

Authors:  Zhonghai Xie; Hongwei Li; Jin Zang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

9.  Induction of cell death by the novel proteasome inhibitor marizomib in glioblastoma in vitro and in vivo.

Authors:  Christa A Manton; Blake Johnson; Melissa Singh; Cavan P Bailey; Lisa Bouchier-Hayes; Joya Chandra
Journal:  Sci Rep       Date:  2016-01-25       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.